Clinical Trials Logo

Clinical Trial Summary

Modern modular foot-orthoses systems allow an integration of the cost and efficiency benefits afforded by the use of pre-formed semi-rigid FOs components, while simultaneously allowing a high degree of individualisation of prescription. Such systems, while popular, still remain unproven. Recent studies in paediatric rheumatology have made a contribution in developing guidelines with regards to pharmacological intervention in arthritic children. In addition, specific drug therapy protocols have been published to effectively help general practitioners, physiotherapists and ophthalmologists to successfully treat children with JIA patients (BSPAR 2006; Hull 2001; NICE guidelines 2002). A Cochrane systematic review on treatment of pes planus, highlighted that children with JIA were excluded as a group from most of the studies (Ashford et al. 2005). At present little evidence exists for the podiatric management of children affected by this disabling pathology, especially for orthotic management. This research has provided evidence to support the use of readily available off-the-shelf FOs in treating JIA children.


Clinical Trial Description

Introduction - Currently there is limited evidence supporting podiatric treatment of children with JIA. The foot orthoses (FOs) prescribed to JIA children so far appeared to be very expensive and required long time to manufacture before the fitting. This randomised controlled trial (RCT) aimed to determine whether pre-formed FOs that can be prescribed at chair side, impacted on pain, quality of life (primary outcomes) and/or gait-parameters (secondary outcomes) in children affected by JIA.

Methods - The study took place at the Gait Analysis laboratory at Queen Margaret University - Edinburgh and at the TORT Centre, Ninewells Hospital-Dundee. Children with JIA were diagnosed according to the ILAR criteria. Intervention was blinded to the patients. The trial group received Slimflex-plus FOs, with the addition of chair side corrections and the control FOs supplied were made with leather board (1mm thick) only. Both FOs had the same black EVA top cover. Primary outcomes were investigated using validated questionnaires (VAS, CHAQ and PedsQL). Tekscan™ equipment (F-Scan™ and HR Walkway®) measured secondary outcomes in-shoe pressure and force data with and without FOs intervention. Multiple foot strikes and repetitive gait patterns were compared pre and post-treatment. Primary and secondary outcome measures were recorded at baseline, 3rd and 6th month's period. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02001844
Study type Interventional
Source University of Newcastle, Australia
Contact
Status Completed
Phase N/A
Start date May 2009
Completion date May 2013

See also
  Status Clinical Trial Phase
Completed NCT00807846 - A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects Phase 4
Completed NCT00279747 - A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA) Phase 3
Completed NCT00652925 - A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA Phase 3
Completed NCT00731965 - Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis Phase 4
Completed NCT02067962 - Identification of Genes Involved in Juvenile Idiopathic Arthritis by Wholel Exome Sequencing N/A
Terminated NCT00868751 - Single Patient Use of Tocilizumab in Systemic Onset Juvenile Idiopathic Arthritis N/A
Terminated NCT00637780 - Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis Phase 4
Completed NCT00001614 - The Safety and Efficacy of Chicken Type II Collagen on Uveitis Associated With Juvenile Rheumatoid Arthritis Phase 1
Completed NCT01412021 - Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis
Enrolling by invitation NCT02377245 - Juvenile Inflammatory Rheumatism (JIR) Cohorte
Completed NCT00426218 - Safety, Efficacy and Pharmacokinetics of Subcutaneous ACZ885 in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) Phase 1/Phase 2
Completed NCT00034853 - Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA) Phase 3
Completed NCT06000566 - Drug Compliance and Affecting Factors in Juvenile Idiopathic Arthritis
Terminated NCT00511329 - Growth Hormone in Children With Juvenile Rheumatoid Arthritis (JRA) and With Crohn's Disease Phase 2/Phase 3
Terminated NCT00688545 - Naturalistic Safety Registry Of Celecoxib (CELEBREX(R)) And NSAIDs In Juvenile Idiopathic Arthritis
Recruiting NCT00012506 - The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis Phase 3